N@N

EBS, COMV, GFF, AMSF, ANX, OSUR Expected To Be Lower Leading Up To Next Earnings Releases

^{Published on 2009-08-03 08:21:49, Last Modified on 2010-12-22 14:40:47 - WOPRAI}
 

August 3, 2009 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released in the coming weeks and determining how the stocks have performed before their last 12 quarterly, 6 quarterly and August earnings reports. Emergent BioSolutions (NYSE: EBS), Comverge (NASDAQ: COMV), Griffon Corp (NYSE: GFF), Amerisafe (NASDAQ: AMSF), Adventrx Pharmaceuticals (AMEX: ANX) and OraSure Technologies (NASDAQ: OSUR) are all expected to be lower leading up to their next earnings release. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act before its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go lower leading up to their next earnings release:

Symbol Company # of Reports Quarter Release Date

EBS Emergent BioSolutions 12 quarters Q2 8/6/2009

COMV Comverge, Inc. 12 quarters Q2 8/6/2009

GFF Griffon Corp 12 quarters Q3 8/6/2009

AMSF Amerisafe, Inc. 12 quarters Q2 8/5/2009

ANX Adventrx Pharmaceutical 12 quarters Q2 8/11/2009

OSUR OraSure Technologies 12 quarters Q2 8/5/2009

Earnings, or profits, drive stock prices. The market values a company based on its current and anticipated future ability to make money. The market takes the earnings pulse of a company four times per year when quarterly reports are issued. When this information is released it can often be a trend-changing or a trend confirming event because the information is so vital to the market's perception of the vitality of that company.

This technology is designed to help the stock trader identify those companies that seem to have a consistent pattern of movement before or after the earnings release date, based on the history of earnings releases for that company. It combines a calendar of expected earnings releases with a history of past earnings releases in a way that lets you see if a pattern exists.

Emergent BioSolutions Inc. (NYSE: EBS), a biopharmaceutical company, focuses on the development, manufacture, and commercialization of vaccines and immune-related therapeutics in the United States, the United Kingdom, and Vietnam. The company offers BioThrax, a vaccine for preventing anthrax infection. Its advanced stage product candidates, which are in Phase II through Phase IV clinical development, include Recombinant protective antigen vaccine that comprises a purified recombinant protein with an alum adjuvant; Anthrax Immune Globulin therapeutic for the treatment of symptomatic anthrax infection; tuberculosis vaccine to prevent tuberculosis; Typhella which is a single-dose, drinkable vaccine for typhoid; Hepatitis B therapeutic vaccine for treating chronic carriers of hepatitis B infection. The companya�s earlier stage development product candidates comprise advanced BioThrax vaccine; Anthrax monoclonal antibody therapeutic, a human monoclonal antibody therapeutic for patients who present symptoms of anthrax disease; Recombinant botulinum vaccine to protect against illness caused by botulinum toxin; and Chlamydia vaccine for administration to adolescents to prevent disease caused by clinically relevant strains of Chlamydia trachomatis. Emergent BioSolutions Inc. has collaborations with Sanofi Pasteur and United Kingdom Health Protection Agency. The company was founded in 1998 and is based in Rockville, Maryland.

Comverge, Inc. (NASDAQ: COMV) provides peaking and base load capacity solutions to electric utilities, grid operators, and associated electricity markets in North America. Its Utility Products and Services segment offers load management solutions, such as the digital control unit, Superstat smart thermostat, In-Home Display, and PowerCAMP load management software to manage, operate, and maintain the electrical load. It also provides advanced meter reading systems, including Maingate Home, Maingate Commercial and Industrial, as well as PowerCAMP metering software to collect, manage, and analyze the use of electrical load. In addition, this segment offers virtual SCADA Systems consisting of digital capacitor control and service reconnect/disconnect devices for electric utilities to monitor and control distribution equipment and systems. The companya�s Residential Business segment provides various solutions that address peak and base load demands for residential and small commercial consumers. This segmenta�s products and services comprise base load capacity program, which offers permanent load reduction through equipment upgrades, energy auditing and consulting, building automation, and lighting retrofits; and virtual peaking capacity program that provides a solution to alleviate stress on the electric grid by aggregating and coordinating the demands of load consuming equipment. It also offers utilities marketing services on an outsourced basis. Its Commercial and Industrial Business segment provides commercial and industrial demand management and energy management services. The demand response services offer commercial and industrial customers with an ability to participate in various demand response programs. The energy management services include the assessment of market opportunities in deregulated and unregulated markets and the performance of energy auditing and implementation strategies. The company was founded in 1974 and is based in East Hanover, New Jersey.

Griffon Corporation (NYSE: GFF), together with its subsidiaries, operates as a manufacturing company primarily in the United States, Germany, the United Kingdom, Canada, and Poland. The company operates in three segments: Electronic Information and Communication Systems, Garage Doors, and Specialty Plastic Films. The Electronic Information and Communication Systems segment specializes in advanced electronic information and communication systems for defense, aerospace, civil, industrial, and commercial applications. It designs, manufactures, sells, and provides logistical support for aircraft communication systems, radar, air traffic management, information and command and control systems, identification friend equipment, integrated homeland security systems, and application specific integrated circuits. This segment also supplies airborne maritime surveillance radar and aircraft intercommunication management systems. The Garage Doors segment manufactures and markets garage doors and sectional doors for use in the residential housing and commercial building markets primarily under Clopay, Ideal Door, and Holmes brand names. This segment also sells related products, such as garage door openers manufactured by third parties. The Specialty Plastic Films segment develops, produces, and sells plastic films and film laminates, including thin gauge embossed and printed films, elastomeric films, and laminates of film and non-woven fabrics used as moisture barriers for disposable infant diapers, adult incontinence products, and feminine hygiene products; and as protective barriers in surgical and industrial gowns, drapes, and equipment covers, as well as used in packaging for hygienic products and house wrap. Griffon Corporation sells its products through direct sales force and sales representatives, as well as through installing dealers, retailers, and wholesalers. The company was founded in 1959 and is headquartered in Jericho, New York.

AMERISAFE, Inc. (NASDAQ: AMSF), through its subsidiaries, markets and underwrites workersa� compensation insurance focused on small to mid-sized employers engaged in hazardous industries, such as construction, trucking, agriculture, logging, oil and gas, maritime, and sawmills. The company offers workersa� compensation insurance policies that provide benefits to injured employees for temporary or permanent disability, death, and medical and hospital expenses. AMERISAFE also provides general liability insurance coverage to its workersa� compensation policyholders in the logging industry. The company sells its products through independent agencies, as well as through its insurance agency subsidiary in 47 states, the District of Columbia, and the U.S. Virgin Islands. AMERISAFE, Inc. was incorporated in 1985 and is based in DeRidder, Louisiana.

ADVENTRX Pharmaceuticals, Inc. (AMEX: ANX), a biopharmaceutical company, focuses on in-licensing, developing, and commercializing proprietary product candidates for the treatment of cancer. Its lead product candidates include ANX-530, a novel emulsion formulations of chemotherapy drug vinorelbine to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin and advanced or metastatic breast cancer; and ANX-514, a novel emulsion formulation of the chemotherapy drug docetaxel for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers. ADVENTRX Pharmaceuticals also holds rights of other compounds that the company is evaluating for future preclinical and clinical development, including ANX-015, a novel formulation of clarithromycin for the treatment of mild to moderate bacterial infections, such as community-acquired pneumonia; ANX-016, an intravenous formulation of vancomycin to treat gram-positive bacterial infections; and ANX-201, a member of a new class of reverse transcriptase inhibitor for a spectrum of antiviral activity against human immunodeficiency virus, human and avian influenza viruses, and herpes simplex viruses. In addition, its other compounds comprise ANX-211, a spectrum antiviral agent formulated to provide antiviral activity against multiple strains of virus; ANX-510, a folate-based biomodulator designed to replace leucovorin as the preferred method to enhance the activity and reduce the associated toxicity of cancer chemotherapeutic agent 5-fluorouracil; ANX-513, a novel formulation of paclitaxel to reduce the need for immunosuppressant premedication associated with administration of Taxol; and ANX-575, a novel formulation of alpha-tocopheryl succinate to facilitate cell death in cancer cells. The company was founded in 1995 is based in San Diego, California.

OraSure Technologies, Inc. (NASDAQ: OSUR) develops, manufactures, and markets oral fluid diagnostic products and specimen collection devices. The companya�s products include OraQuick ADVANCE HIV-1/2, a point-of-care test for antibodies to the human immunodeficiency virus (HIV) type 1 and type 2; OraQuick HIV-1/2 OTC, a point-of-care oral fluid HIV-1/2 test; OraQuick HCV, a point-of-care test for antibodies to the hepatitis C virus; OraSure, an oral fluid collection device for the detection of antibodies to HIV-1; and Intercept, an oral fluid collection device used for oral fluid drugs of abuse testing. It also offers MICRO-PLATE DOA Assays for the detection of drugs in an oral fluid sample; cryosurgical systemsa"professional for the removal of warts and benign skin lesions; and cryosurgical systemsa"OTC for the removal of common and plantar warts. In addition, OraSure Technologies provides immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot HIV-1 confirmatory test; and Q.E.D., a point-of-care saliva alcohol test. It develops Homogeneous DOA Assays; cryosurgical systemsa"OTC for an indication other than common warts or plantar warts; and OraQuick, a point-of-care testing platform. Further, the company provides various diagnostic products, including immunoassays and in vitro diagnostic tests that are used on other specimen types, and medical devices. OraSure Technologies sells its products through direct sales, strategic partnerships, and independent distributors to clinical laboratories, hospitals, clinics, community-based organizations and public health organizations, distributors, government agencies, physiciansa� offices, and commercial and industrial entities in the United States, Europe, and internationally. It has collaboration agreements with Roche Diagnostics and Schering-Plough Corporation. The company was founded in 1979 and is based in Bethlehem, Pennsylvania.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com

One example from the SqueezeTrigger database is approximately 2.5 billion short sale transactions going back to January 1, 2005, and SqueezeTrigger calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data. Total Short Interest is the number of shares shorted but not yet covered, and is different from total short volume. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com

Go to www.SqueezeTrigger.com to find out the exact price that the entire Total Short Interest will start covering!

About SQUEEZETRIGGER.COM

WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.

SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha�s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.

Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.squeezetrigger.com +1-800-715-9999 Tom@squeezetrigger.com

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641